lipitor and lopid
Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. 8.3 Nursing Mothers It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. It is especially important to check with your doctor before combining Lipitor with any of the following: Antacids Clofibrate Colestipol Cyclosporine Digoxin Drugs that suppress the immune system Erythromycin Fenofibrate Fluconazole Gemfibrozil Itraconazole Ketoconazole Niacin Oral contraceptives Special information if lipitor and lopid are pregnant or breastfeeding Developing babies need plenty of cholesterol, so this cholesterol-lowering drug should never be used during pregnancy. Lipitor can be administered as a single dose at any time of the day, with or without food. Your doctor may do blood tests to check your liver before you start taking Lipitor, and while you take it. Cardiovascular Analysis lipitor and lopid study data has shown an increased risk of hemorrhagic stroke in patients treated with atorvastatin who had a stroke or TIA within 6 months preceding treatment compared to placebo. Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of Lipitor 80 mg with clarithromycin (500 mg twice daily) compared to that of Lipitor alone . 2.6 Dosage lipitor and lopid Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or a Combination of Ritonavir plus Saquinavir or Lopinavir plus Ritonavir In patients taking cyclosporine, therapy should be limited to Lipitor 10 mg once daily. These side effects have happened only to a small number of people. 64 events in the placebo group), HR 0.58, 95.1% lipitor and lopid (0.39, 0.86) (p=0.007). The overall risk reduction was consistent regardless of age (less than lipitor and lopid greater than or equal to 65) or gender. Overview of Efficacy Results in TNT Endpoint Atorvastatin 10 mg (N=5006) Atorvastatin 80 mg (N=4995) HR* (95%CI) PRIMARY ENDPOINT n (%) n (%) First major cardiovascular endpoint 548 (10.9) 434 (8.7) 0.78 (0.69, 0.89) Components of the Primary Endpoint CHD death 127 (2.5) 101 (2.0) 0.80 (0.61, 1.03) Non-fatal, non-procedure related MI 308 (6.2) 243 (4.9) 0.78 (0.66, 0.93) Resuscitated cardiac arrest 26 (0.5) 25 (0.5) 0.96 (0.56, 1.67) Stroke (fatal and non-fatal) 155 (3.1) 117 (2.3) 0.75 (0.59, 0.96) SECONDARY ENDPOINTS† First CHF with hospitalization 164 lipitor and lopid 122 (2.4) 0.74 (0.59, 0.94) First PVD endpoint 282 (5.6) 275 (5.5) 0.97 (0.83, 1.15) First CABG or other coronary revascularization procedure‡ 904 (18.1) 667 (13.4) 0.72 (0.65, 0.80) First documented angina endpoint‡ 615 (12.3) 545 (10.9) 0.88 (0.79, 0.99) All-cause mortality 282 (5.6) 284 (5.7) 1.01 (0.85, 1.19) Components of All-Cause Mortality lipitor and lopid death 155 (3.1) 126 (2.5) 0.81 (0.64, 1.03) Noncardiovascular death 127 (2.5) 158 (3.2) 1.25 (0.99, 1.57) lipitor and lopid death 75 (1.5) 85 (1.7) 1.13 (0.83, 1.55) Other non-CV death 43 (0.9) 58 (1.2) 1.35 (0.91, 2.00) Suicide, homicide, and other traumatic non-CV death 9 (0.2) 15 (0.3) 1.67 (0.73, 3.82) HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=myocardial infarction; CHF=congestive heart failure; CV=cardiovascular; PVD=peripheral vascular disease; CABG=coronary artery bypass graft Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons * Atorvastatin 80 mg; atorvastatin 10 mg † Secondary endpoints not included in primary endpoint ‡ Component of other secondary endpoints Of the events that comprised the primary efficacy endpoint, treatment with Lipitor 80 mg/day significantly reduced the rate of non-fatal, lipitor and lopid related MI and fatal and non-fatal stroke, but not CHD death or resuscitated cardiac arrest (Table 5). In rare cases, Lipitor can cause a condition that results in the breakdown of lipitor and lopid muscle tissue, leading to kidney failure. Take Lipitor by mouth with or without food. Store at room temperature. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the lipitor and lopid recommended dose. Storage instructions... If you lipitor and lopid any of these other conditions, you may need lipitor and lopid adjust your Lipitor dose or lipitor and lopid special tests: history of liver disease; history of kidney disease; diabetes; a thyroid disorder; or if you drink more than 2 alcoholic beverages daily. Special warnings about Lipitor There is a slight chance of liver damage from Lipitor, so your doctor lipitor and lopid order a blood test to check your liver function before you start taking the drug, again 12 weeks after you begin therapy or your dosage is increased, and periodically thereafter.
Online pharmacy Tags
150 151 152 153 154 155 156 157 158
.
